Provided by Tiger Fintech (Singapore) Pte. Ltd.

Eyenovia Inc.

1.13
+0.04003.67%
Post-market: 1.130.00000.00%18:49 EDT
Volume:23.01K
Turnover:25.51K
Market Cap:3.20M
PE:-0.02
High:1.15
Open:1.10
Low:1.09
Close:1.09
Loading ...

Eyenovia Inc - Implementing a Reduction in Force Affecting Approximately 50% of Its Workforce

THOMSON REUTERS
·
16 Nov 2024

Eyenovia Inc - Remaining Staff Will Be Focused on Optejet((Reg))Gen-2 Development

THOMSON REUTERS
·
16 Nov 2024

Sector Update: Health Care Stocks Slide Late Afternoon

MT Newswires Live
·
16 Nov 2024

Eyenovia Cut to Market Perform From Outperform by William Blair

Dow Jones
·
16 Nov 2024

Eyenovia Cut to Hold From Buy by Brookline Capital

Dow Jones
·
16 Nov 2024

Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline

Benzinga
·
16 Nov 2024

S&P 500 Down Over 1%; US Retail Sales Top Expectations

Benzinga
·
16 Nov 2024

Eyenovia Shares Plumb New Depths After Study Failure

Dow Jones
·
16 Nov 2024

Eyenovia downgraded to Market Perform from Outperform at William Blair

TIPRANKS
·
15 Nov 2024

William Blair Downgrades Eyenovia to Market Perform From Outperform

MT Newswires Live
·
15 Nov 2024

Eyenovia Shares Fall 63% to 12 Cents After Co to Discontinue Late-Stage Study for Eye Drug

THOMSON REUTERS
·
15 Nov 2024

Brookline Capital Downgrades Eyenovia to Hold From Buy

MT Newswires Live
·
15 Nov 2024

Sector Update: Health Care Stocks Decline Premarket Friday

MT Newswires Live
·
15 Nov 2024

BUZZ-Eyenovia discontinues late-stage eye drug study, shares fall

Reuters
·
15 Nov 2024

Eyenovia to Consider 'Strategic Options' After Phase 3 Study Fails to Meet Primary Endpoint

MT Newswires Live
·
15 Nov 2024

Eyenovia Shares Plunge More Than 50% to 16 Cents Premarket After Co to Discontinue Late-Stage Study for Eye Drug

THOMSON REUTERS
·
15 Nov 2024

Eyenovia Mulls Options After Phase 3 Study Failure

Dow Jones
·
15 Nov 2024

Eyenovia Third Quarter 2024 Earnings: Misses Expectations

Simply Wall St.
·
15 Nov 2024

Eyenovia to discontinue late-stage study for eye drug

Reuters
·
15 Nov 2024

BRIEF-Eyenovia Provides Update On Phase 3 Chaperone Study

Reuters
·
15 Nov 2024